肺栓塞:基于指南的风险分层和治疗决策更新的实用方法
María Barca-Hernando1, Luis Jara-Palomares1,2
1Respiratory Department, Hospital Virgen del Rocio, Sevilla, Spain.
Expert review of respiratory medicine
|December 22, 2023
概括
肺栓塞 (PE) 风险分层对于患者护理至关重要. 目前的工具有助于识别高风险PE患者,但需要一个新的模型来更好地管理那些有崩风险的患者.
科学领域:
- 心脏病学 心脏病学
- 肺部病理学 肺部病理学
- 紧急医疗 紧急医疗
背景情况:
- 肺栓塞 (PE) 是全球死亡的一个重要原因.
- 准确的风险分层指导PE患者的治疗策略和护理环境.
- 评估包括症状,并发症和右心功能障碍.
研究的目的:
- 审查目前用于PE风险分层的工具.
- 为了确定管理高风险PE患者的局限性.
- 为个性化PE管理引入一种新的概念模型.
主要方法:
- 评估现有的PE风险分层工具和指南.
- 分析诸如sPESI,Bova,FAST和Hestia之类的风险评分.
- 专家就急性PE管理的新框架达成共识.
主要成果:
- 目前的指导方针将PE分为高风险,中等风险和低风险组.
- 风险评分 (sPESI,Bova,FAST,Hestia) 有助于确定患者的风险水平.
- 需要改进的框架来管理PE患者的血液动力学崩的风险.
结论:
- 现有的风险分层工具有助于PE管理,但存在局限性.
- 一个由专家驱动的新模型正在开发中,用于全面的PE风险评估.
- 对于急性PE患者来说,个性化管理策略至关重要,特别是那些有崩风险的患者.
相关概念视频
Pulmonary Hypertension: Classification and Pathogenesis
188
Pulmonary hypertension (PH) is a severe health condition in which the mean pulmonary arterial pressure increases to 25 mmHg or more, even when the body is at rest. This high pressure in the blood vessels that transport blood from the heart to the lungs can cause various symptoms, including shortness of breath, can lead to right heart failure, and significantly affect the overall quality of life.
There are various classifications for PH, each relating to different underlying causes and also...
There are various classifications for PH, each relating to different underlying causes and also...
188
Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists
170
Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
170
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
187
Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
187
Pneumonia III: Complications and Assessment
237
Pneumonia poses the potential for numerous complications that warrant consideration. These complications include the following:
237
Pneumonia IV: Management
332
The treatment of pneumonia varies based on its severity and the causative pathogen. Here is a structured approach to managing pneumonia, integrating pharmaceutical and supportive care strategies.
Bacterial Pneumonia Treatment
For bacterial pneumonia, antibiotics serve as the cornerstone of therapy. Initial treatment often begins with empirical antibiotics, tailored to the anticipated causative organism and adjusted based on culture results. Key antibiotic choices include:
Bacterial Pneumonia Treatment
For bacterial pneumonia, antibiotics serve as the cornerstone of therapy. Initial treatment often begins with empirical antibiotics, tailored to the anticipated causative organism and adjusted based on culture results. Key antibiotic choices include:
332
Chronic Obstructive Pulmonary Disease-V: Management
2.5K
Managing Chronic Obstructive Pulmonary Disease (COPD) involves a multifaceted approach to reduce symptoms, prevent exacerbations, improve overall health status, and slow disease progression. Key strategies include lifestyle modifications, pharmacotherapy, supportive therapies, and, in some cases, surgery. Here is an overview of the primary COPD management strategies:
Smoking Cessation
Smoking Cessation
2.5K


